WO2012094615A3 - Use of cav3.1 selective t-type calcium channel antagonists - Google Patents
Use of cav3.1 selective t-type calcium channel antagonists Download PDFInfo
- Publication number
- WO2012094615A3 WO2012094615A3 PCT/US2012/020518 US2012020518W WO2012094615A3 WO 2012094615 A3 WO2012094615 A3 WO 2012094615A3 US 2012020518 W US2012020518 W US 2012020518W WO 2012094615 A3 WO2012094615 A3 WO 2012094615A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- type calcium
- calcium channel
- selective
- channel antagonists
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is directed to heterocyclic compounds which are antagonists of T-type calcium channels and which are useful in the treatment and prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to methods of identifying a compound for the treatment and prevention of Alzheimer's Disease by investigating T-type calcium channel blocking activity of the compound.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161430827P | 2011-01-07 | 2011-01-07 | |
US61/430,827 | 2011-01-07 | ||
US201161450913P | 2011-03-09 | 2011-03-09 | |
US61/450,913 | 2011-03-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012094615A2 WO2012094615A2 (en) | 2012-07-12 |
WO2012094615A3 true WO2012094615A3 (en) | 2012-08-30 |
Family
ID=46457728
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/020518 WO2012094615A2 (en) | 2011-01-07 | 2012-01-06 | Use of cav3.1 selective t-type calcium channel antagonists |
PCT/US2012/020515 WO2012094612A1 (en) | 2011-01-07 | 2012-01-06 | Method of treating essential tremor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/020515 WO2012094612A1 (en) | 2011-01-07 | 2012-01-06 | Method of treating essential tremor |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2012094615A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3364993T3 (en) | 2015-10-22 | 2023-01-09 | Cavion Inc | APPROACHES TO THE TREATMENT OF ANGELMAN SYNDROME |
US20210128537A1 (en) * | 2016-12-21 | 2021-05-06 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
US11130750B2 (en) | 2017-02-15 | 2021-09-28 | Cavion, Inc. | Calcium channel inhibitors |
MX2019012818A (en) * | 2017-04-26 | 2020-07-14 | Cavion Inc | Methods for improving memory and cognition and for treating memory and cognitive disorders. |
WO2018200844A1 (en) * | 2017-04-26 | 2018-11-01 | Cavion, Inc. | Methods for treating dravet syndrome |
CN113164393A (en) | 2018-10-03 | 2021-07-23 | 卡维昂公司 | Treatment of essential tremor using (R) -2- (4-isopropylphenyl) -N- (1- (5- (2,2, 2-trifluoroethoxy) pyridin-2-yl) ethyl) acetamide |
CN114340670A (en) | 2019-07-11 | 2022-04-12 | 普拉克西斯精密药物股份有限公司 | Formulations of T-type calcium channel modulators and methods of use thereof |
KR20240021760A (en) * | 2021-05-19 | 2024-02-19 | 아미리어드 파마 아이엔씨. | Treatment methods for Alzheimer's disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070213267A1 (en) * | 2005-09-30 | 2007-09-13 | The Board Of Trustees Of The University Of Illinois | Peptides and Calcium Regulation in Mammalian Cells |
US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
US20100204247A1 (en) * | 2007-10-04 | 2010-08-12 | Duffy Joseph L | N-substituted oxindoline derivatives as calcium channel blockers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008132139A2 (en) * | 2007-04-27 | 2008-11-06 | Ucb Pharma S.A. | New heterocyclic derivatives useful for the treatment of cns disorders |
BRPI0920927A2 (en) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | azaquinolinone derivatives and uses thereof |
-
2012
- 2012-01-06 WO PCT/US2012/020518 patent/WO2012094615A2/en active Application Filing
- 2012-01-06 WO PCT/US2012/020515 patent/WO2012094612A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070213267A1 (en) * | 2005-09-30 | 2007-09-13 | The Board Of Trustees Of The University Of Illinois | Peptides and Calcium Regulation in Mammalian Cells |
US20100204247A1 (en) * | 2007-10-04 | 2010-08-12 | Duffy Joseph L | N-substituted oxindoline derivatives as calcium channel blockers |
US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
Also Published As
Publication number | Publication date |
---|---|
WO2012094612A1 (en) | 2012-07-12 |
WO2012094615A2 (en) | 2012-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012094615A3 (en) | Use of cav3.1 selective t-type calcium channel antagonists | |
PH12018500960A1 (en) | Processes for preparing isoquinolinones and solid forms of isoquinolinones | |
HRP20190491T1 (en) | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | |
MX2020001602A (en) | Lfa-1 inhibitor and polymorph thereof. | |
BR112014014276A2 (en) | compound, pharmaceutical composition, method for inhibiting a receptor kinase, and methods for treating conditions, diseases and / or disorders, and pain | |
WO2012040641A3 (en) | Compounds for treating neurodegenerative diseases | |
WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
MX2014010589A (en) | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE. | |
EA201390711A1 (en) | HYDROXYAMIDE COMPOUNDS OF Pyrimidine As Inhibitors of Protein Deacetylases and Methods for Their Use | |
EA201391485A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
WO2012173682A3 (en) | Compounds and methods for the treatment of isocitrate dehydrognase related diseases | |
UA113750C2 (en) | COMPOSITION (+) - 2- $ 1- (3-ethoxy-4-methoxyphenyl) -2-methanesulfonylethyl] -4-ACETYLAMINOISOINDOLINE-1,3-DIONE | |
WO2012122058A3 (en) | Alkyne substituted quinazoline compound and methods of use | |
WO2013016720A3 (en) | Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases | |
WO2012040636A3 (en) | Compounds and methods for treating diseases mediated by protease activated receptors | |
WO2012065102A3 (en) | S-t-butyl protected cysteine di-peptide analogs and related compounds | |
WO2012002687A3 (en) | Methods for treating bipolar disorder | |
MX2013002851A (en) | Inhibitors of notum pectinacetylesterase and methods of their use. | |
WO2012112674A3 (en) | Compounds and methods of use thereof for treating neurodegenerative disorders | |
MX370253B (en) | Compositions of jasmonate compounds and methods of use. | |
PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
WO2012174488A3 (en) | Agents and methods for treating ischemic and other diseases | |
MX2013002956A (en) | Arylosulfonamides for the treatment of cns diseases. | |
EP2681209A4 (en) | Compounds and methods for the treatment of pain and other disorders | |
EA201270610A1 (en) | HINUCLIDINE COMPOUNDS AS ALPHA-7 ACETYL-CHOLINE RECEPTOR LIGANDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12732332 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 14/10/2013) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12732332 Country of ref document: EP Kind code of ref document: A2 |